BioNTech SE and Pfizer (PFE) recently received a positive recommendation from the European Medicines Agency for marketing ...

Pfizer (PFE) is currently under significant scrutiny due to a study linking its product, Depo-Provera, to increased health risks, and an associated Multi-District Litigation could have influenced its ...

But it's the Pfizer case that seems to me to be a more important harbinger of the challenges companies may face as they try to encourage diversity and inclusion in the workplace.

Pfizer (NYSE:PFE) and BioNTech (NASDAQ:BNTX), its partner for the Comirnaty COVID-19 vaccine, made legal submissions to London's Court of Appeal on Thursday seeking to overturn a prior court ruling ...

Pfizer and the direct purchasers entered into the settlement agreement Nov. 22. The agreement still needs official court approval. More articles on legal & regulatory issues: ...

Oct 3 (Reuters) - An advocacy group that opposes diversity initiatives in medicine urged a federal appeals court on Tuesday to revive its lawsuit claiming a fellowship program offered by Pfizer ...

The 2nd U.S. Circuit Court of Appeals ruled in favor of Pfizer (PFE), in a lawsuit by Do No Harm challenging the company's diversity fellowship program. Read more here.

Pfizer and its German partner BioNTech asked London's Court of Appeal on Thursday to overturn a ruling that their COVID-19 vaccine infringed one of Moderna's patents, in the latest round of a ...

Pfizer said its Wyeth unit has agreed to pay a $784.6 million settlement for cases related to the calculation of Medicaid rebates for a gastric drug sold between 2001 and 2006, according to Reuters.

In the latest chapter of the legal saga, Pfizer and BioNTech are pressing the U.S. Patent and Trademark Office (PTO) to invalidate a pair of Moderna patents tied to mRNA vaccine production.

'Ongoing challenges' force Pfizer to scrap oral RSV med from ReViral buyout. By Gabrielle Masson Oct 8, 2024 4:58pm. Pfizer ReViral RSV R&D. In another blow to its $525 million ...

Pfizer (PFE) and BioNTech (BNTX) challenge Moderna's patent win in London court over mRNA COVID-19 vaccine technology. Read more here.